Arch Therapeutics (ARTH) Downgraded by Ifs Securities

Arch Therapeutics (OTCMKTS:ARTH) was downgraded by analysts at Ifs Securities from a “strong-buy” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday.

Several other equities research analysts also recently commented on ARTH. ValuEngine downgraded shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. Zacks Investment Research raised shares of Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a report on Friday, December 1st. Finally, HC Wainwright set a $3.00 price objective on shares of Arch Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Arch Therapeutics has an average rating of “Hold” and a consensus price target of $2.17.

Shares of Arch Therapeutics (OTCMKTS:ARTH) opened at $0.31 on Wednesday. The company has a market cap of $49.68, a PE ratio of -7.65 and a beta of 0.52. Arch Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $0.89.

COPYRIGHT VIOLATION NOTICE: “Arch Therapeutics (ARTH) Downgraded by Ifs Securities” was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply